US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
SPCX
$146.90
▼-0.40%
AAPL
$343.91
▼-1.10%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
SPCX
$146.90
▼-0.40%
AAPL
$343.91
▼-1.10%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by LAVA Therapeutics N.V.
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Announces Annual Meeting of Shareholders
June 10, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 16, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 22, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
August 14, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
June 14, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
June 08, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
June 01, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Announces Annual Meeting of Shareholders
May 30, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
April 11, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
March 09, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
February 16, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
February 09, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
February 06, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
January 23, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Appointment of New Directors to the Board
January 06, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 16, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
November 03, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 03, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
November 01, 2022
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Tickers
LVTX
